BX004 clinical trials

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection

This study looks at a new mist treatment for adults with Cystic Fibrosis (CF) who have ongoing lung infections caused by Pseudomonas aeruginosa bacteria. We want to see if this treatment, called BX004, can reduce the amount of bacteria in their lungs after 8 weeks.